RIBOMIC completes patient enrollment in early phase II study of umedaptanib pegol for Achondroplasia
RIBOMIC Inc., a Tokyo-based leader in aptamer therapeutics, has reported significant progress in its early phase II study of umedaptanib pegol. This breakthrough involves treating pediatric patients with Achondroplasia, a rare genetic disorder characterized by short stature and limb shortening. Early Phase II Study Progresses The company has successfully enrolled 13 children aged 5 to […]